Legal Representation
Attorney
Ryan A. McGonigle
USPTO Deadlines
Next Deadline
903 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2022-01-18)
Due Date
January 18, 2028
Grace Period Ends
July 18, 2028
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
20 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Jan 18, 2022 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| Dec 17, 2021 | SUNA | E | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | Loading... |
| Dec 16, 2021 | SUPC | I | STATEMENT OF USE PROCESSING COMPLETE | Loading... |
| Dec 16, 2021 | CNPR | P | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | Loading... |
| Dec 13, 2021 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL | Loading... |
| Nov 12, 2021 | IUAF | S | USE AMENDMENT FILED | Loading... |
| Nov 12, 2021 | EISU | I | TEAS STATEMENT OF USE RECEIVED | Loading... |
| May 11, 2021 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Mar 16, 2021 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Mar 16, 2021 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Feb 24, 2021 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Feb 5, 2021 | XAEC | I | EXAMINER'S AMENDMENT ENTERED | Loading... |
| Feb 5, 2021 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | Loading... |
| Feb 5, 2021 | GNEA | F | EXAMINERS AMENDMENT E-MAILED | Loading... |
| Feb 5, 2021 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Feb 5, 2021 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN | Loading... |
| Feb 1, 2021 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Oct 28, 2020 | MDSM | E | NOTICE OF DESIGN SEARCH CODE E-MAILED | Loading... |
| Oct 27, 2020 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Sep 21, 2020 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
PHARMACEUTICAL PREPARATIONS FOR THE TREATMENT OF DISEASES AND DISORDERS OF THE CENTRAL AND PERIPHERAL NERVOUS SYSTEM, MOVEMENT DISORDERS, PARKINSON'S DISEASE AND PARKINSONIAN DISORDERS, AND RESTLESS LEGS SYNDROME
First Use Anywhere:
20200400
First Use in Commerce:
20200400
Additional Information
Design Mark
The mark consists of the stylized wording "ONGENTYS (OPICAPONE) CAPSULES" combined with a design of two curved lines.
Color Claim
Color is not claimed as a feature of the mark.
Pseudo Mark
ONGENTYS OPICAPONE CAPSULES
Classification
International Classes
005
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"(OPICAPONE) CAPSULES"